New England-Israel Business Council
2010 Life Sciences Summit
October 18-19, 2010 Hosted by the Brandeis International Business
School
2010 Life Sciences Summit
1
Summit Ad_IBS_FINAL.qxp:Layout 1
10/5/10
2:41 PM
Page 1
The Economist ranked us among the
top business schools in the world—
four years in a row.
Learn why at brandeis.edu/global
PRogram
Program Contents
Summit Sponsors ................................................................................................................................................ 2
Welcome from the Governor of Massachussetts .......................................................................... 3
Welcome from Brandeis International Business School ........................................................... 4
Welcome from NEIBC ......................................................................................................................................... 5
Program .................................................................................................................................................................. 6-7
Dinner Program and Presenter Bios .................................................................................................9-10
Speakers ............................................................................................................................................................11-18
Presenting Company Overviews ....................................................................................................20-33
NEIBC Overview .................................................................................................................................................. 35
NEIBC Board of Directors.............................................................................................................................. 36
NEIBC Life Sciences Committee .............................................................................................................. 37
Partners..................................................................................................................................................................... 38
Program book design by Anadon Communications www.anadonpr.com
Printing by RR Donnelley www.rrd.com
2010 Life Sciences Summit
1
We would like to thank the following sponsors for their support of the NEIBC 2010 Life Sciences Summit:
Platinum Sponsors
Gold Sponsors
Silver Sponsors
FABER DAEUFER
ROSENBERG
950 Winter Street
Suite 4500
Waltham, MA 02451
www.fdrpc.com
MOITI
Massachusetts Office of International Trade & Investment
Contributing Sponsors
Government of Israel
Economic Mission to North America
2
2010 Life Sciences Summit
Consulate General of Israel
to New England
Welcome
3
Dear participants,
Brandeis International Business School is proud to welcome you to the 2010 New EnglandIsrael Life Sciences Summit.
We are delighted to host an event that explores collaboration between Israel and
Massachusetts in the life sciences arena at a time when innovating economies around the
world are seeking new paths to promote their advanced technologies.
This initiative helps create relationships among the most innovative companies in Israel and
New England. We are pleased to provide the venue for Israeli entrepreneurs to meet with
strategic partners and venture capitalists who appreciate their contributions to the life sciences
revolution. In addition, by featuring leading industry speakers who will address life science
policy issues, new technology adoption and other compelling issues, we hope to cover the full
spectrum of this important and vibrant sector of the global economy.
Whether through biotechnology or pharmaceuticals, medical devices or drug delivery, the
summit underscores Brandeis’s commitment to nurture intellectual and business connections
between U.S. and Israeli companies. We salute each of the participants for providing a critical
span in this important cross-border bridge. The life sciences community can indeed create a
more prosperous world by working together at the fruitful intersection of scientific discovery
and business partnership.
This event also embodies the basic premise underlying the creation of the Brandeis
International Business School. The study of globalization is truly at the heart of our mission.
Our students are the emerging business leaders and public policy-makers of tomorrow – we
hope you will take the opportunity to meet and interact with them during the summit.
With best regards,
Bruce R. Magid
Dean, Brandeis International Business School
Martin and Ahuva Gross Chair in Financial Markets and Institutions
4
Welcome
Dear participants,
On behalf of the New England Israel Business Council, it is our great pleasure to welcome you
to the 2010 Life Sciences Summit.
This Summit brings together representatives from New England and Israel, two of the most
innovative regions in the world, making significant contributions to better understanding
of the human body, development of new pharmaceutical, biological and device-based
treatments, and for the delivery of high quality care. Numerous relationships among
companies, clinicians, researchers and investors already exist, connecting New England and
Israeli organizations. The goal of the New England Israel Business Council is to help expand
on these collaborations, including joint research and development activities, licensing,
manufacturing, marketing and investments.
With a growing number of local organizations seeking innovative technologies in Israel,
and as the local area is becoming the home for many Israelis for their U.S. operations, this
collaboration contributes to the economic strength of both regions, who share so much in
common. The 2010 Life Sciences Summit is intended to foster additional relationships.
We appreciate the time devoted by all speakers and their willingness to share their experiences
and knowledge with the attendees from both the U.S. and Israel, the visiting delegates from
Israel, who are here to demonstrate the depth of life sciences activities in Israel, and the local
supporters, sponsors and volunteers that made this event possible.
We wish all of you a successful conference,
Sincerely,
Yuval Malinsky
President
NEIBC
David Barone
Chair
Life Sciences Committee
Welcome
5
PRogram
Day 1
Monday, October 18
Brandeis University Hassenfeld Conference Center
415 South Street, Waltham MA 02454
8 – 8:45 a.m.
Registration, breakfast and networking
8:45 – 9 a.m.
Opening Remarks:
Yair Shiran, Economic Minister to North America, Government of Israel Economic Mission
9 a.m. – noon
Value Creation by Life Sciences Companies: How to Deal with Concerns and Challenges Facing Health Care Providers, Payers, Policy Makers and Investors
Healthcare providers face increasing cost pressures, growing demand for quality and safety and mounting new government mandates. A distinguished group of experts will explore the challenges of providers and health plans as they
determine when to adopt new technologies and how to afford them, as well as how the complex environment affects
investors in companies that have already developed innovative products but are yet to cross the market acceptance
chasm.
Panel Discussions
Moderators:
Stephen Weiner, Partner, Chair of the Health Law Practice, Mintz Levin
Eyal Zimlichman, M.D., Brigham and Women’s Hospital
Jon Kravetz, Partner, Chair of the Securities Practice, Mintz Levin
1. The Hospitals’ Dilemma: New Technologies — Pros and Cons
David Bates, M.D., Chief of Division of General Internal Medicine, Brigham and Women’s Hospital
Eric Halvorsen, Ph.D., Director, Technology & Innovation Technology Office, Children’s Hospital, Boston
Leslie Selbovitz, MD, Chief Medical Officer and Senior Vice President for Medical Affairs, Newton-Wellesley Hospital
2. Insurance Companies’ Expectations of New Technologies
Michael Berelowitz, M.D., Senior Vice President and Head of Clinical Development and Medical Affairs, Pfizer
Thomas Hawkins, M.D., Medical Director, Health Informatics, Blue Cross Blue Shield of Massachusetts
Charles Petrie, Ph.D., Head, Outcomes Research Clinical Development and Medical Affairs Specialty Care, Pfizer
3. Financing Challenges for Later Stage Life Science Companies
Fredrick Frank, Vice Chairman, Peter J. Solomon Company
Jami Rubin, Managing Director, Global Investment Research, Goldman Sachs
Ido Schoenberg, M.D., Chairman and Chief Executive Office, American Well Corporation
Noon – 1 p.m.
Lunch
1 – 3 p.m.
Massachusetts-Israel Life Sciences Collaborations
Companies rooted in both places have a long and often successful shared history of creating effective and profit-making
products and services. Why have Massachusetts and Israel been so well-suited to collaboration, and what’s ahead? Gain
insights from the leaders of the state’s economic agencies and the biopharma and medical device councils - how to best
collaborate with Massachusetts companies and government, and hear the findings of new research about the size and
character of the shared economic success of Israel and the Bay State.
1. Leveraging Israeli Innovation in Massachusetts: Results of New Research
David Goodtree, Advisor, New England Israel Business Council
2. Case Studies: Successful Israeli Originated Companies Operating in MA
Shimon Eckhouse, Chairman, Syneron, OrSense, CardioDex, NanoCyte, Tulip, Navotek, Rapid Medical
Paul Valentine, President and Chief Executive Officer, Sleep HealthCenters
3. Today and Tomorrow in Massachusetts
Ted Carr, Executive Director, Massachusetts Office of International Trade & Investment
Robert Coughlin, President and CEO, Massachusetts Biotechnology Council
Tom Sommer, President, Massachusetts Medical Device Industry Council
Susan Windham-Bannister, Ph.D., President and CEO, Massachusetts Life Sciences Center
6
2010 Life Sciences Summit
Program
Day 1 Evening Program Monday, October 18
Newton Marriott Hotel
2345 Commonwealth Avenue, Newton MA 02466
4 – 6 p.m.
The Israel Life Sciences Industry: An Overview and Case Presentations
Moderator: David Barone, Principal, Boston MedTech Advisors
Ora Dar, Ph.D., Head of Life Science Sector, Office of the Chief Scientist, Israel Ministry of Industry Trade and Labor
Israeli Life Science companies CEOs (see list – Day 2)
6 – 7 p.m.
Pre-Dinner Reception and Networking
7 – 10 p.m.
2010 Summit Dinner
Keynote Speaker: Professor Aaron Ciechanover, 2004 Nobel Laureate, Technion – Israel Institute of Technology
(Details, Pages 8 & 9)
Day 2 Tuesday, October 19
Brandeis University Hassenfeld Conference Center
415 South Street, Waltham MA 02454
7:30 – 8:30 a.m.
Registration, breakfast and networking
8:30 – 9:30 a.m.
Funding Life Sciences Companies — Perspectives from U.S. and Israeli Venture Capitalists
Moderator: Stephen Ferruolo, Partner, Goodwin Procter
Erez Chimovitz, Partner, OrbiMed Israel
Michal Geva, Co-Founder and General Partner TriVentures L.P.
Amir Nashat, General Partner, Polaris Venture Partners
Elizabeth Stoner, M.D., Managing Director, MPM Capital
9:30 a.m. – 12:30 p.m.
Presentations, Israeli Life Sciences Companies
Track A:
Moderator: Zvi Ladin, Ph.D., Principal, Boston MedTech Advisors
Elminda
Ronen Gadot, Managing Director
ITGI Medical
Israel Schreiber, Chief Executive Officer
Mazor Surgical Technologies
Ori Hadomi, Chief Executive Officer
Navotek Medical
Giora Kornblau, Chief Executive Officer
Neuronix
Eyal Baror, Chief Executive Officer
NovoCure
William Doyle, Chairman
Regentis Biomaterials
Alastair Clemow, Ph.D., President and Chief Executive Officer
Track B:
Moderator: Yael Biran, Managing Director, Mintz Levin Israel Business
Biokine Therapeutics
Yossi Riback, Chief Executive Officer
Dynamix Pharmaceuticals
Oren Becker, Ph.D., President and Chief Executive Officer
GalMed Medical Research
Allen Baharaff, Chief Financial Officer
NasVax
Ronald Ellis, Ph.D., Chief Scientific Officer
Protalix
Sandra Lauterbach, Vice President, Sales and Commercial Operation
Proteologics
Danny Taglicht, Ph.D., Director Research & Development
TransPharma Medical
Daphna Heffetz, Ph.D., Chief Executive Officer
12:30 – 2 p.m.
Lunch
Speakers:
Stuart Altman, Ph.D., The Heller School for Social Policy and Management, Brandeis University
Paul Levy, CEO, Beth Israel Deaconess Medical Center
2 – 3:30 p.m.
Building Successful Life Science Companies in 2010 — Lessons from Experienced Entrepreneurs
Moderator: Alan Crane, General Partner, Polaris Venture Partners
Bob Connelly, CEO, Pulmatrix
Hezi Himelfarb, CEO, IceCure Medical
Stan Lapidus, President and CEO, SynapDx; Founder of Cytyc, EXACT Sciences and Helicos BioSciences
Amar Sawhney, President and CEO, Ocular Therapeutix; Director and Founder, AccessClosure
3:30 – 6 p.m.
Private meetings with visiting companies
2010 Life SciencesProgram
Summit
7
Dinner Program
Opening remarks
Yuval Malinsky
President, New England-Israel Business Council
Bruce Magid
Dean, Brandeis International Business School
Patient story
Matt Murray
Velcade Patient
Introduction
Alfred Goldberg, Ph.D.
Professor of Cell Biology, Harvard Medical School
Keynote Speaker
Aaron Ciechanover
2004 Nobel Prize Laureate
Professor, Technion – Israel Institute of Technology
Professor Aaron Ciechanover
Aaron Ciechanover was born in Haifa, Israel, in 1947. He is a distinguished professor in
the Technion – Israel Institute of Technology in Haifa. He received his M.Sc. (1971), M.D.
(1975) from the Hebrew University in Jerusalem, and his D.Sc. (1982) from the Technion.
There, as a graduate student with Dr. Avram Hershko and in collaboration with Dr. Irwin
A. Rose from the Fox Chase Cancer Center in Philadelphia, they discovered that covalent
attachment of ubiquitin to a target protein signals it for degradation. They deciphered
the mechanism of conjugation, described the general proteolytic functions of the
system, and proposed a model according to which this modification serves as a recognition signal for a specific downstream protease.
As a post-doctoral fellow with Dr. Harvey Lodish at the M.I.T., he continued his studies
on the ubiquitin system and made additional important discoveries. It is now clear that
ubiquitin-mediated proteolysis plays major roles in numerous cellular processes, and
aberrations in the system underlie the pathogenesis of many diseases, among them
certain malignancies and neurodegenerative disorders. Consequently, the system has
become an important platform for drug development. For his groundbreaking studies,
Dr. Ciechanover received numerous prize , among them the 2000 Albert Lasker Award,
the 2003 Israel Prize, and the 2004 Nobel Prize in chemistry (shared with Hershko and
Rose). He is a member of many prestigious academies among them the National Academy of Sciences (U.S.), the Israeli Academy of Sciences and Humanities, and the Institute
of Medicine of the National Academies (U.S.)
8
Program
Dinner Program
Yuval Malinsky,
President, New England-Israel Business Council
CEO, Vigorous Mind, Inc.
Yuval Malinsky, president of the New England-Israel Business Council is CEO of Vigorous Mind, Inc. of Newton, Mass.,
a brain wellness software company. Mr. Malinsky has 25 years of experience in software and healthcare technology in
the U.S., Europe, and Israel. He was founder and CEO/managing director of three software and software services companies and has worked as business consultant to Fortune 500 companies, academic institutions and medical device
companies. Mr. Malinsky was a mentor at MIT Venture Mentoring Service for five years and taught a graduate course
in emerging technologies in health care at Northeastern University SPCS where he also developed a health informatics master’s program. He is an advisory board member of several health technology companies and a member of the
board of governors of the Jerusalem College of Engineering. Mr. Malinsky holds an MBA from INSEAD in Fontainebleau, France, and a B.A. in computer science and economics from Bar-Ilan University in Israel. He is a retired major in
the Israel Defense Force.
Bruce Magid, Ph.D.
Dean, Brandeis University International Business School
Martin and Ahuva Gross Chair in Financial Markets and Institutions
Bruce R. Magid has served as dean of the International Business School since August 2007. He serves as treasurer and
board member of the Massachusetts Office of International Trade and Investment. He was previously dean of the College of Business and the founding dean of the Lucas Graduate School of Business at San José State University. Prior to
joining San José State, Magid was the founding executive director of MSU Global, Michigan State University’s online
and global distance education business unit. Before entering academic administration, Dr. Magid provided leadership as a managing director and senior vice president at Bank of America, where he served for 21 years, managing a
variety of units, including international economic policy research groups and Latin America division corporate finance.
Dr. Magid holds a multidisciplinary Ph.D. in international economics, business law and comparative politics from the
Fletcher School at Tufts University.
Matt Murray
Massachusetts State Trooper
Matt Murray is a husband and father of two boys. The Northborough, Mass., native also is a person
living with multiple myeloma. Despite the challenges he’s faced, he keeps a positive attitude. He
loves being involved with his sons, coaching Little League and being a Cub Scout den leader.
He continues to work with his doctors in fighting his disease, and he continues to educate
others. Murray feels that by speaking out, he’s making a difference for others. As a Millennium Ambassador, Matt was able to throw out the ceremonial first pitch at Fenway Park
this year. Through the program, he meets many other cancer survivors. Matt encourages
other families to persevere and take their diagnoses head on. He hopes that sharing his
personal experience will inspire and motivate others living with multiple myeloma to live
their lives to the fullest.
Alfred Goldberg, Ph.D
Professor of Cell Biology, Harvard Medical School
Alfred Goldberg, a professor of cell biology at Harvard Medical School, has been on the faculty of that institution for
nearly his entire academic career. His important discoveries have concerned the biochemical mechanisms and physiological regulation of protein breakdown in cells and the importance of this process in human disease. His laboratory first demonstrated the non-lysosomal ATP-dependent pathway for protein breakdown, which is now termed the
ubiquitin-proteasome pathway. He and his colleagues also first introduced proteasome inhibitors that are now widely
used as research tools. He also initiated the efforts that led to the development of the proteasome inhibitor, Bortezomib (Velcade), currently widely used in the treatment of multiple myeloma. Dr. Goldberg received his A.B. degree in
biochemistry and his Ph.D. in physiology in 1968 from Harvard University, after attending Cambridge University and
Harvard Medical School. His accomplishments have been recognized with many awards and honored with many
distinguished lectureships. He is a fellow of the American Academy of Arts & Sciences and has served on scientific
advisory boards for a number of biotechnology companies, was a founder of ProScript, and has been a consultant to a
number of major pharmaceutical companies.
Program
9
MILLENNIUM CONGRATULATES THE NEIBC
ON THEIR COMMITMENT TO JOIN TOGETHER
THE RESOURCES OF NEW ENGLAND’S
BIOTECH COMMUNITY WITH THE TALENTS
AND EXPERTISE OF ISRAEL’S DYNAMIC LIFE
SCIENCE INDUSTRY. WE ALSO SALUTE, DR.
AARON CIECHANOVER FOR HIS SCIENTIFIC
LEGACY WHICH CONTINUES TO TOUCH
CANCER PATIENTS WORLDWIDE.
Image: Colored scanning electron micrograph
(SEM) of a lymphoma cancer cell.
One focus: a shared commitment to improve the
lives of cancer patients everywhere.
Now the innovative science of a leading American biopharmaceutical company joins the global assets of
Takeda, Japan’s largest pharmaceutical company, for a global commitment to oncology.
Millennium: The Takeda Oncology Company is developing an extensive pipeline — among the top in oncology
worldwide — with more than 17 compounds in development for a broad range of solid and hematological cancers.
Our pipeline — rich in novel compounds — includes multiple candidates that target seven disease pathways:
protein homeostasis, anti-angiogenesis, growth-signaling inhibition, cell-cycle inhibition, apoptosis, hormone
regulation and immunomodulation.
We are dedicated to a strong partnership with the oncology community. Together we can make a dramatic
impact on cancer therapeutics over the next decade.
WHAT IS YOUR WISH?
Visit 1000cranesofhope.com to help in the advancement of
research and patient support.
To learn more, visit us at millennium.com.
©2010 Millennium Pharmaceuticals, Inc. All rights reserved.
10
Program
As each person’s wishes and dreams join ours, Millennium will
make a charitable donation to benefit several professional and
charitable organizations.
SPEAKER BIOS
Stuart Altman, Ph.D.
Stuart Altman is the Sol C. Chaikin Professor of National Health Policy at the Heller
School of Social Policy and Management,
Brandeis University. He is an economist
whose research interests are primarily in
the area of federal and state health policy.
Dr. Altman served 12 years as chairman of
the congressionally legislated Prospective
Payment Assessment Commission (ProPac)
formed to advise Congress and the administration on the functioning of the Medicare Diagnostic Related
Group (DRG) hospital payment system and other system
reforms. He is also chair of The Health Industry Forum, which
brings together diverse group leaders from across the health
care field to develop solutions for critical problems facing the
health care system. Dr. Altman has a B.B.A. from the City College
of New York and an M.A. and Ph.D from University of California,
Los Angeles.
David Barone
David Barone is principal, Boston MedTech Advisors. His background consists of 25 years experience in the health care and
medical industry in the U.S., including general, technical and
operations management, strategic planning, marketing and
business development. Mr. Barone held senior management
positions in a number of medical device companies, overseeing
product development, marketing, pilot manufacturing, clinical
evaluations, regulatory affairs and intellectual properties. In
addition, he is an accomplished entrepreneur, founding, financing and growing several health care service organizations. Mr.
Barone has consulted and assisted U.S. and off-shore medical
technology organizations, ranging from start-ups to Fortune
500 companies, in diverse areas including market development, opportunity analysis, regulatory and reimbursement
strategies, business development, financing and more. He has
a B.Sc. from the Technion — Israel Institute of Technology, M.Sc.
and M.B.A., Rensselaer Polytechnic Institute.
David Bates, M.D
David Bates is an internationally renowned expert in using
information technology to improve clinical decision-making,
patient safety, quality-of-care, cost-effectiveness, and outcomes
assessment in medical practice. A practicing general internist,
Dr. Bates is chief of the Division of General Internal Medicine
and Primary Care at Brigham and Women’s Hospital in Boston, a
professor of medicine at Harvard Medical School, and a professor of health policy and management at the Harvard School
of Public Health, where he co-directs the Program in Clinical
Effectiveness. He also serves as medical director of clinical and
quality analysis for Partner’s Health care Systems. Dr. Bates is a
graduate of Stanford University and the Johns Hopkins School
of Medicine. He also has an M.Sc. in health policy and management from the Harvard School of Public Health.
Proudly Supports
New England-Israel Business Council
2010 Life Sceince Summit
Offering Expert Commercial and Private Banking
Services to Local Customers.
For more information about our local services,
Please contact:
Sean Lane, SVP
Private Banking
(212) 782 2051
SLane@Hapoalimusa.com
NY Branch Member FDIC
Lee Stenner, SVP
Middle Market Lending
(212) 782 2181
LStenner@Hapoalimusa.com
www.hapoalimusa.com
Speaker Bios
11
Michael Berelowitz, M.D
Michael Berelowitz is currently senior vice president and head
of clinical development and medical affairs in the Specialty
Care Business Unit at Pfizer, Inc. Dr. Berelowitz joined Pfizer
in 1996 as a medical director in the diabetes clinical research
team. Among his public activities, Dr. Berelowitz has served on
the board of directors of the American Diabetes Association,
the Clinical Initiatives Committee of the Endocrine Society, and
has chaired the Task Force on Research of the New York State
Council on Diabetes. He also has served on several editorial
boards, including the Journal of Clinical Endocrinology and
Metabolism, Endocrinology, Reviews in Endocrine and Metabolic
Disorders and Clinical Diabetes. Dr. Berelowitz has authored and
co-authored more than 100 peer-reviewed journal articles and
book chapters in the areas of pituitary growth hormone regulation, diabetes and metabolic disorders.
Yael Biran
Yael Biran is managing director, Mintz Levin Israel Business.
Prior to joining Mintz Levin, Ms. Biran served as corporate attorney for Koor Industries, Inc., an Israeli company traded on the
NYSE, and for Menora Gaon Capital Markets Group. She has also
practiced as a litigation attorney at Dr. J. Weinroth & Co., and for
the Israel Union for Environmental Defense (IUED), a non-governmental organization advocating environmental issues. Ms.
Biran received her LL.B. from Tel Aviv University (1991), where
she concentrated on commercial law and economic analysis
of law, and has completed mediation training from the Israel
Center for Negotiation and Conflict Management (ICN) (1998).
Ted Carr
Ted Carr is executive director, Massachusetts Office of International Trade and Investment. Previously, he was chief of staff for
the Executive Office of Housing and Economic Development
and special assistant at the Commerce Department. Mr. Carr
holds a B.A. degree from Cornell College and M.P.A. from Harvard University, Kennedy School of Government.
Erez Chimovits
Erez Chimovits is a managing director, OrbiMed Israel. He has
14 years of operational experience, including 10 years of senior
managerial experience in publicly traded biotech companies. Mr. Chimovits until recently served as the CEO of NasVax
(TASE:NSVX), a company developing improved vaccine and
immunotherapeutic products. Under his leadership NasVax acquired Protea and struck agreements with GlaxoSmithKline and
Novartis. Previously, Mr. Chimovits spent more than seven years
with Compugen (Nasdaq:CGEN), most recently as president,
Compugen USA Inc. and executive VP, commercial operations,
Compugen Ltd. At Compugen, he had P&L responsibility for
more than 100 people and led multiple transactions with blue
chip pharmaceutical companies including Johnson & Johnson,
Novartis, Teva, Abbott, Medarex and others. Mr. Chimovits
earned his MBA, M.Sc., and his B.Sc. from Tel Aviv University.
Bob Connelly
Bob Connelly, CEO of Pulmatrix, has 25 years of experience
in the life sciences sector including the last 14 years in serial
entrepreneurial pursuits. Prior to joining Pulmatrix, Mr. Connelly was the founding CEO of Domantis, Ltd., a drug discovery
company developing a pipeline of novel therapies based on
12
Speaker Bios
the next generation of antibody molecules, fully human domain antibodies (dAbs). He sold Domantis to GlaxoSmithKline
for $454 million in cash, the largest valuation paid for a preclinical biotechnology company. Prior to Domantis, Mr. Connelly
spent six years with Bioveris, Inc. (formerly IGEN and since
acquired by Roche) in the roles of senior vice president of sales
and marketing and general manager of IGEN’s life sciences unit.
Mr. Connelly spent the first 11 years of his career with Abbott
Laboratories in sales, marketing and management positions.
Robert Coughlin
Robert Coughlin is president and CEO of the Massachusetts
Biotechnology Council. He is familiar with all areas of the
Massachusetts life sciences super cluster and is a passionate
advocate for research and the biotechnology community. Mr.
Coughlin has spent his career in both the public and private
sectors, most recently serving as undersecretary of economic
development within Gov. Deval Patrick’s administration in
2007. Prior to that, he was elected as state representative to the
11th Norfolk district for three terms. In the world of business he
specialized in the environmental services industry and moved
on to capital management and venture capital. He has held
senior executive positions in both fields. He is a graduate of the
Massachusetts Maritime Academy where he majored in marine
engineering, and is a lieutenant in the U.S. Naval Reserve.
Alan Crane
Alan Crane is general partner, Polaris Venture Partners. From
2006 to 2009, Mr. Crane co-founded and served as CEO of Cerulean Pharma (a nanotechnology focused pharmaceutical company) and co-founded Visterra Inc. (a vaccine company). From
2002 until 2006, Mr. Crane was president and CEO of Momenta
Pharmaceuticals. He joined Momenta as the fifth employee
and built the company into a public company, creating an
advanced and diversified pipeline, entering into two strategic
collaborations with the Sandoz division of Novartis, and raising
$275 million. Prior to this, he was senior vice president of global
corporate development at Millennium Pharmaceuticals. Prior
to Millennium, Mr. Crane was a marketing executive at DupontMerck and a consultant with the Boston Consulting Group and
Arthur D. Little. He has a B.A. and MBA from Harvard University.
Ora Dar, Ph.D
Ora Dar is the head of the life sciences sector at the Office of
the Chief Scientist at the Israeli Ministry of Industry & Trade and
the consultant for biotechnology to the Chief Scientist. Dr. Dar
is responsible for defining and implementing the support of
research and development in life sciences companies and for
enhancing the networking between academia and industry.
This has lead to the initiation and maturation of several viable
programs, such as funding academic applied research, dedicated scheme for biotechnology incubator(s), tracks enabling
collaboration with global life sciences companies, tools for upgrading infrastructures, and a special government backed Bio
Fund (in process). Previously, Dr. Dar spent 16 years in academic
research (mostly at the Weizmann Institute of Science), several
years in the industry, and 10 years as a consultant to venture
capital and investment firms as well as foreign funds and international R&D programs. Dr. Dar is a medical sciences graduate
of the Hebrew University of Jerusalem and holds a Ph.D. from
the University of London.
Shimon Eckhouse
Shimon Eckhouse is the chairman of Syneron Ltd., OrSense Ltd.,
CardioDex Ltd., NanoCyte Ltd., Tulip Ltd., Navotek Ltd., Rapid
Medical Ltd. and RealView Ltd. Dr. Eckhouse was a co-founder
of ColorChip Inc. and served as its Chairman from 2003 to January 2004 and again since 2007, and as its Chief Executive Officer
from 2001 to 2003. Dr. Eckhouse was the chairman and CEO
of ESC Medical Systems from its inception in 1992 until 1999.
Prior to founding ESC Medical Systems, Dr. Eckhouse was head
of product development and technical director at Maxwell
Technologies in San Diego, California. Before that, Dr. Eckhouse was a scientist, team leader and head of a department
in Rafael, Armament Development Authority of Israel and was
active in various areas of research and development, including
lasers and electro-optics. Dr. Eckhouse holds a B.Sc. in physics
from the Technion Israeli Institute of Technology and a Ph.D.
in physics from the University of California at Irvine. He has
more than 20 registered patents and has published more than
50 papers in leading reference journals and conferences. He is
also a member of the board of directors of the Technion Israeli
Institute of Technology.
Stephen Ferruolo
Stephen Ferruolo is a partner in the business law department
at Goodwin Procter and member of the technology companies
& life sciences and M&A/corporate governance practices and
chair of the firm’s San Diego office. He specializes in the life
sciences industry and has worked on public and private financings, acquisitions, joint ventures, strategic partnerships and
technology licenses for companies in such fields as biotechnol-
ogy, medical devices and diagnostics. Mr. Ferruolo has an active
Israeli company practice and has worked with Israeli life science
companies since late 1990s. Mr. Ferruolo is a member of the
American, California and San Diego bar associations and serves
as the vice president and general counsel of BIOCOM. Prior to
joining Goodwin Procter in 2007, Mr. Ferruolo was co-chair of
the corporate/VLG practice group at Heller Ehrman LLP and
a member of the intellectual property transactions practice
group. He previously served as co-chair of Heller Ehrman’s Life
sciences practice group. From 1979 to 1987, Mr. Ferruolo was
an assistant professor of history at Stanford University.
Fredrick Frank
Frederick Frank is vice chairman, Peter J. Solomon Company.
Mr. Frank joined the firm in 2009 from Barclays Capital where he
was Vice Chairman. He began his investment banking career at
Smith, Barney & Co. Inc. in 1958, where he attained the positions of co-head of research, vice president and director. Subsequently he joined Lehman Brothers, Inc., in 1969, as a partner.
At Lehman, Mr. Frank provided investment banking services
to an extensive number of companies in the pharmaceutical,
biotechnology, health care services, medical device and nutraceutical industries, and was involved in hundreds of financings,
strategic alliances and merger and acquisition transactions in
the global health care industry. Mr. Frank holds a B.A. from Yale
University and an MBA from Stanford University.
Michal Geva
Michal Geva has over a decade of extensive hands-on experience in Israeli and American medical device companies, includ-
You have the ideas.
We know how to get them to market.
Boston MedTech Advisors helps medical technology and healthcare
providers to achieve their business goals by providing ethical, resultsoriented, professional and cost-effective advice and services.
Strategy | Planning | Execution
U.S. Boston MedTech Advisors, Inc.
990 Washington Street
Dedham, MA 02026
Ph. 781.407.0900
Europe Boston MedTech Advisors Europe, GmbH
Am Pastorenwaldchen 2
D-44229 Dortmund, Germany
Ph. +49.231.973022.10
www.bmtadvisors.com
IBC &
E
N
f
o
r
e
t
r
o
Proud supp
mit
m
u
S
s
e
c
n
e
the Life Sci
Speaker Bios
13
ing ByPass, a developer of a cardiovascular anastomotic device
(collaborated with J&J), AST, a developer of a stent and stent
delivery system (acquired by Boston Scientific for $120 million),
and GI View, a developer of advanced endoscope technologies
for the GI tract. She has held executive roles in regulatory &
clinical affairs, quality assurance and marketing, and has served
as an advisor to several American companies with R&D centers
in Israel. In 2007 Ms. Geva co-founded TriVentures, an early
stage medical device venture based in Israel, together with Dr.
Peter Fitzgerald and Dr. Marty Leon.
David Goodtree
David Goodtree is a technology marketer turned community
volunteer. In his professional life, Goodtree was VP marketing of
Akamai Technologies during the company’s successful commercial launch and IPO, and later as VP strategy, initiated the
company’s portfolio of strategic investments. Previously, Goodtree served as group director at Forrester Research where he
led industry analysts researching the networking, telecom, and
computing industries. Goodtree also managed product development for MCI’s virtual network services and the firm’s global
partnerships. Since leaving the technology industry, Goodtree
has dedicated his time to serving community organizations
locally and nationally.
Erik Halvorsen, Ph.D.
Erik Halvorsen is director of technology and business development for Children’s Hospital Boston where he oversees and
manages the Technology and Innovation Development Office
responsible for translating Children’s renowned laboratory
and clinical research into devices, therapeutics, diagnostics
and informatics products. Prior to joining Children’s Hospital,
Dr. Halvorsen was the director of business development at
Harvard University’s Office of Technology Development and
the Harvard Stem Cell Institute. Dr. Halvorsen also has worked
at the University of Virginia Patent Foundation and its forprofit subsidiary, Spinner Technologies Inc. He holds a B.A.
from the University of Virginia, M.S. from the Medical College
of Virginia, and a Ph.D. in neuropharmacology from the University of Virginia.
Thomas Hawkins, M.D.
Thomas Hawkins is the Blue Cross Blue Shield of Massachusetts
medical director for health informatics. He is responsible for
clinical development and presentation of health informatics,
providing our employer customers with population-based
reporting linking financial, utilization, and clinical data, and
data-driven suggestions for health management and prevention interventions. As a board certified internist, Dr. Hawkins
practiced primary care for 11 years in Peabody and at the
Beverly Hospital, and is a clinical instructor at Harvard Medical
School in population health and clinical epidemiology, with a
master’s in health policy and management from the Harvard
School of Public Health. Dr. Hawkins primary experience is in
developing, and helping employers act on, comparative cost
and quality data, and understanding their perspective — including six years as the New England Federal Reserve Bank’s
medical director. At Harvard Pilgrim Health Care for 20 years, Dr.
Hawkins was the director, eHealth strategy and associate medical director for employer health programs.
14
Speaker Bios
Hezi Himelfarb
Hezi Himelfarb became CEO of IceCure in July 2008, having
joined the company from Remon Medical Technologies, Inc.
During his eight years at Remon, he raised $39 million from
U.S. and Israeli venture capital funds and led the 45-employee
company from an early stage incubator start-up through several innovation and development cycles, including successful
human trials in the U.S, Europe, India and Israel. At the end of
2008, Mr. Himelfarb led the acquisition of Remon by Boston Scientific for $100+ million and additional future earn-outs. Prior
to Remon, Mr. Himelfarb spent four years in Medtronic InStent
Israel, where he managed the company’s Israeli facility, which
designed and manufactured coronary and peripheral stents.
Mr. Himelfarb also led the integration of InStent into Medtronic’s vascular group, which conducted several worldwide animal
and clinical trials with its newly developed stents. He spent 14
years at Scitex Corporation, where he held positions including
engineering manager, hardware designer, software programmer and project leader. Mr. Himelfarb holds a B.Sc. in electronic
engineering and an MBA, both from Tel Aviv University.
Jon Kravetz
Jon Kravetz is a member of the Mintz Levin law firm’s Boston office, chairing the securities practice group and serving as one of
the core members of the biotechnology and high technology
practice groups. He represents clients in both public and privately placed equity and debt financings, provides counseling
for public companies with respect to the full range of securities compliance issues and advises high technology, emerging
biotechnology and medical device companies in contractual
and strategic matters. Mr. Kravetz has an active international
practice, representing European companies in merger and
acquisition, financing and other transactions with U.S. and
non-U.S. companies. Mr. Kravetz received his B.A. from Williams
College, where he was elected to Phi Beta Kappa, and his J.D.
from Stanford Law School.
Zvi Ladin, Ph.D.
Zvi Ladin has over 20 years of management experience in the
medical industry, government and academia, focusing on
clinical applications, regulatory affairs and reimbursement
strategies. His experience includes establishing reimbursement and regulatory strategies for therapeutic and diagnostic
medical device companies, submission of regulatory applications, including 510(k) and PMAs for products in class I-III and
drug-device combination products. Dr. Ladin has represented
companies in negotiations with the FDA, European and Asian
regulatory agencies, and served for five years as a scientific
advisor to the U.S. Food and Drug Administration. Dr. Ladin, a
recipient of the Whitaker Fellowship and International Research
Awards, taught mechanical and biomedical engineering at MIT
and Boston University. He holds a B.Sc., aeronautical engineering and M.Sc., biomedical engineering, both from the Technion,
Israel Institute of Technology, and a Ph.D., medical engineering,
MIT-Harvard Medical School / Division of Health Science and
Technology.
Stanley N. Lapidus
Stanley Lapidus is a co-founder, president and CEO at SynapDx
Corp. Mr. Lapidus is also the co-founder and CEO at Helicos
Biosciences Corporation. He has been an executive chairman
of the firm since 2007 and also served as its president. Mr.
Lapidus is an experienced life sciences entrepreneur. He serves
as a venture advisor at Flagship Ventures and has served as an
entrepreneur-in-residence at OneLiberty Ventures since 1995.
He founded and served in leadership roles in many companies,
including EXACT Sciences Corp., Cytyc Corp., and Itran Corp.
Mr. Lapidus has also served as chairman and director for EXACT
and Precision Therapeutics, Inc. He is a member of the business
advisory board at Excel Medical Ventures, chairman of Valeo
Business Advisory Board for Valeo Medical, Inc. and served as
director of TransMedics, Inc. He also serves as an advisor to the
Harvard MIT Division of Health Services and Technology, research assistant professor in the pathology department of Tufts
University Medical School, senior lecturer of MIT’s Sloan School,
lecturer at Harvard Medical School, member of the advisory
board for Cooper Union School of Engineering, and member of
advisory board for the Harvard School of Public Health’s Center
for Cancer Prevention. Mr. Lapidus holds a B.S. degree in electrical engineering from Cooper Union.
Paul Levy
Paul Levy was named in 2002 as president
& CEO of Beth Israel Deaconess Medical
Center, one of the nation’s top-ranked hospitals. Formerly executive dean of administration at Harvard Medical Center, executive director of the Massachusetts Water
Resources Authority, Mr. Levy, a long-time
administrator, is the only non-physician to
head a major Harvard-affiliated academic
GOOD
MATCH
hospital. Levy holds bachelor’s degrees in economics and urban
studies, and a master’s degree in city planning from MIT. He is a
longtime proponent of openness of information in the healthcare sector, and is one of the few CEOs of a major hospital to
write his own blog, www.runningahospital.blogspot.com. He
is also a member of the MIT Corporation and the Board of ISO
New England. He is the co-author of Negotiating Environmental
Agreements, 1999.
Amir Nashat
Amir Nashat is a general partner in Polaris Ventures’ Boston
office. Dr. Nashat joined Polaris in April 2002 and focuses on investments in the life sciences. Prior to joining Polaris, Dr. Nashat
completed his Ph.D. as a Hertz fellow in chemical engineering at MIT with a minor in biology under the guidance of Dr.
Robert Langer. During his time at MIT, Dr. Nashat completed an
internship in the London office of Goldman, Sachs & Company.
Dr. Nashat currently represents Polaris as a director of aTyr
Pharmaceuticals, Avila Therapeutics, BIND Biosciences, Fate
Therapeutics, Living Proof, Pervasis Therapeutics, Promedior
Pharmaceuticals and Selecta Biosciences. Dr. Nashat played an
instrumental role in the inception of Living Proof, Pervasis and
Sun Catalytix Corporation, serving as the founding president
of all three companies. Additionally, Dr. Nashat has served as
a director of Adnexus Therapeutics (acquired by Bristol Myers Squibb), Athenix Corp. (acquired by Bayer), and Hydra
Biosciences, and as an Observer of GI Dynamics and Advion.
Dr. Nashat currently serves on the board of the New England
Venture Capital Association, on the venture advisory committee of the IAVI Innovation Fund, on the advisory board of the
Counsel to U.S. and Israeli companies
that are pioneering innovative medical
solutions. 70+ attorneys with dedicated
industry expertise advise on securing IP
rights, financings, partnering and strategic
alliances, regulatory issues, M&A and
accessing capital markets.
For additional information, please contact:
Stephen Ferruolo
858.202.2710
sferruolo@goodwinprocter.com
Boston | Hong Kong | London | Los Angeles | New York | San Diego | San Francisco | Silicon Valley | Washington DC | www.goodwinprocter.com
Speaker Bios
15
Simmons School of Management Entrepreneurship Initiative,
and is a catalyst of the Deshpande Center for Technological
Innovation at MIT. Prior to obtaining his Ph.D. at MIT, Dr. Nashat
earned both his B.S. and M.S. in materials science and mechanical engineering at the University of California, Berkeley.
Charles Petrie, Ph.D.
Charles Petrie was awarded his degree in clinical psychology,
concentration in behavioral medicine, from the University of
Georgia in 1990. He completed his clinical training in behavioral medicine and clinical neuropsychology at Brown University Medical School and is a licensed psychologist. Dr. Petrie
joined the outcomes research group at Pfizer Global R&D in
1996 and is currently head for outcomes research in specialty
care, where he leads outcomes strategy and evidence development for product differentiation and lifecycle planning
to support risk-investment decision making and to enable
formulary access and reimbursement. Prior to his career at
Pfizer, Dr. Petrie held staff and clinical faculty appointments
in the Department of Psychology and the Department of
Physical Medicine and Rehabilitation at the University Medical Center of East Carolina University School of Medicine. He
was a managing partner and director of clinical services at
the Institute for Behavioral Medicine in Providence, where
he was also a project director of health services research for
Abacus Self-insured Employers Risk Management Association,
and consulted to managed health care organizations in New
England. Among other contributions to professional societies and external advisory boards, Dr. Petrie represents Pfizer
on the FDA-Critical Path Institute Patient Reported Outcomes
Coordinating Committee. His work in outcomes research has
been presented at professional conferences and workshops,
and published in peer-reviewed journals.
Jami Rubin
Jami Rubin is business unit leader of the Healthcare Research
Group at Goldman Sachs, as well as lead analyst for the large
cap and specialty pharmaceutical sectors. She joined Goldman
Sachs as a managing director in 2008 after working at Morgan
Stanley, where she was named managing director in 2000 and
led the large cap and specialty pharmaceutical research team.
Previously, she was a managing director at Wertheim Schroder, which she joined in 1994. Ms. Rubin has been recognized
by Institutional Investor magazine, the Greenwich Survey and
Starmine as one of the leading analysts covering the sector. She
earned a B.A. in history from Vassar College in 1985.
Amar Sawhney, Ph.D.
Amar Sawhney is an entrepreneur whose inventions are the
founding basis for several medical device and biotechnology companies and their products. Dr. Sawhney holds over
80 patents and has authored more than 100 publications and
scientific abstracts. Dr. Sawhney is currently President and CEO
of Ocular Therapeutix Inc. (formerly iTherapeutix) and also of
Augmenix, Inc. He also serves as managing member of Incept
LLC, a medical device incubator. Prior to Ocular Therapeutix, Dr.
Sawhney was co-founder, president and CEO of Confluent Surgical (acquired in 2006 by Covidien), chairman of MarketRx Inc.
(acquired by Cognizant in 2007), and director and technology
founder of Focal, Inc. (FOCL, acquired by Genzyme), co-founder
of Access Closure, Inc. In addition to Ocular Therapeutix, he
16
Speaker Bios
serves on the board of Soteira, Augmenix, TiE Boston, and
Ostial Corporation.
Ido Schoenberg, M.D.
Ido Schoenberg serves as the chairman and CEO of American Well Corporation and oversees the company’s corporate
strategy. Dr. Schoenberg has a lengthy track record of successfully leading technology companies in the health care field. In
1996, together with Phyllis Gotlib, he co-founded iMDSoft, a
provider of enterprise software that automates hospital critical
care units. He grew the company into a market leader with a
large multinational install base in the U.S., Europe and East Asia.
In 2001, Dr. Schoenberg joined CareKey Inc. as CEO and took
the company through its acquisition by the TriZetto group. Dr.
Schoenberg served as TriZetto’s chief business strategy officer
until 2006. Dr. Schoenberg continues to serve as the chairman
of iMDSoft’s scientific advisory board. He received his M.D. from
the Sackler School of Medicine.
Leslie Selbovitz, M.D.
Les Selbovitz is the chief medical officer and senior vice
president for medical affairs at Newton-Wellesley Hospital and
a Clinical Professor of Medicine at Tufts University School of
Medicine in Boston. Dr. Selbovitz has spent his career as both a
board-certified internist and as a leader in engaging physicians
in peer review programs to improve quality, safety and efficiency while reducing legal liability. He spends considerable time
thinking about the relationships of the physician and hospital
to the individual patient, and the more complex one to society,
and emphasizes the doctor-patient relationship as the core of
ethical decision making. He is an innovator in teaching medical
staffs to use peer review approaches to analyze and anticipate
adverse events and to report actual adverse outcomes to the
Board of Registration in Medicine. Making knowledge and evidence available in the flow of patient care to improve decision
making has been central to his order set design. Dr. Selbovitz
has led the Newton-Wellesley Hospital’s large growth in clinical
research and its being one of the first 12 organizations in the
U.S. to achieve accreditation through the Association for the
Accreditation of Human Research Protection Programs, the
only federally recognized accreditation program in the U.S.
Under Dr. Selbovitz’s leadership, Newton-Wellesley Hospital has
achieved national recognition and several prestigious awards
for its provision of high quality and safe care.
Yair Shiran
Yair Shiran assumed the post of Israel economic minister to
North America in 2006. Prior to arriving in the U.S., Mr. Shiran
served as Israel’s chief negotiator, representing Israel in trade
negotiations with many of its key trading partners, including
the U.S., Canada, Egypt, Turkey and the World Trade Organization (WTO). From 1996-2001, Mr. Shiran was Israel’s representative to the WTO in Geneva, Switzerland. He has also been an
adjunct professor at the Tel Aviv University School of Government’s Program on Diplomacy, the Hebrew University’s School
of Business Administration and Fox Business School at Temple
University in Philadelphia. Mr. Shiran received his M.A. in public
administration from Harvard University’s Kennedy School of
Government and his MBA and B.A. from The Hebrew University
in Jerusalem.
Thomas Sommer
Tom Sommer was named the first president of the Massachusetts Medical Device Industry Council (MassMEDIC) in October
1996, where he serves as the association’s chief executive
officer, managing its day-to-day operations and working with
medical device industry executives in developing its policy
agenda. Previously Mr. Sommer was a vice president of the
Massachusetts Technology Collaborative, where he managed
external relations and research activities for this quasi-state
agency from 1994-1996. He was vice president for policy
and communications of the New England Council, a regional
business organization, from 1989-1994; deputy director of the
Massachusetts Office of Federal-State Relations in Washington,
D.C. and Boston from 1983-1987 and a legislative assistant
at the National Association of Development Organizations, a
Washington-based association of local economic development
officials. Mr. Sommer received his B.A. in political science from
Boston College and a master’s degree in public administration
from the John F. Kennedy School of Government at Harvard
University.
Elizabeth Stoner, M.D.
Elizabeth Stoner joined MPM in 2007 following a 22-year career
at Merck Research Laboratories. She is currently managing
director at MPM, and also serves as chief development officer
of Rhythm Pharmaceuticals. At the time of her retirement from
Merck, Dr. Stoner was senior vice president of global clinical
development operations with responsibility for the company’s
clinical development activities in more than 40 countries. She
also oversaw the clinical development activities of Merck’s
Japanese partner Banyu, led the clinical development for the
Merck/Schering-Plough joint venture for Zetia/Vytorin, and
played a critical leadership role in Merck’s efforts to transform
its worldwide clinical development operations. Earlier in her
career at Merck, Dr. Stoner led the Proscar clinical development
program from inception, establishing Merck as a leader in the
field of prostate disease. As endocrine therapeutic head, Dr.
Stoner’s responsibilities included all steroid and lipid metabolism, as well as the growth hormone secretagogue clinical research programs. Prior to Merck, she was an assistant professor
of pediatrics at Cornell University Medical College. Dr. Stoner
received a B.S. in chemistry from Ottawa University, Kansas, an
M.S. in chemistry from the State University of New York at Stony
Brook, and an M.D. from Albert Einstein College of Medicine.
Paul Valentine
Paul Valentine is the CEO of Sleep HealthCenters. In the past, he
has served as president and chief financial officer of Children’s
Medical Ventures (now owned by Philips Respironics, Inc.) and
chief financial officer of both Cape Cod Potato Chip Co. and The
Boston Popcorn Co. Mr. Valentine holds a B.S. in accounting and
MBA from Babson College. He is chair of the American Academy of Sleep Medicine’s Practice Development Advisory Council,
board member of the North East Sleep Society, and a member
of the National Sleep Foundation’s Development Committee.
Stephen Weiner
Stephen (Steve) Weiner is a partner with Mintz Levin and chairs
its health law practice. He has over 30 years of experience in
the health care field as a policy maker, educator and attorney.
Speaker Bios
17
Mr. Weiner works with health care services providers in undertaking strategic positioning, structuring payor strategies and
clinical integration initiatives, mergers, acquisitions, strategic
affiliations, “demergers” and joint venture arrangements. He
also assists in the structuring and monitoring of relationships
between hospitals and physicians and handles a wide variety
of regulatory and reimbursement matters. Mr. Weiner has
taken an active role in the development and implementation
of Massachusetts’ signature health care reform program and in
implementing Massachusetts’ initiative to create a state-wide
interoperable electronic health record system. Mr. Weiner has
been listed in the health law section of The Best Lawyers in
America since the section originated in Who’s Who in America.
Mr. Weiner is a graduate of Harvard College and of Yale Law
School.
Susan Windham-Bannister, Ph.D.
Susan Windham-Bannister is the first president and CEO of
the Massachusetts Life Sciences Center, a quasi-public entity
created by the Legislature in 2006 to promote the life sciences
industry within Massachusetts. The center is at the heart of the
state’s new $1 billion life sciences law and is fast becoming the
hub of connectivity for all sectors of the life sciences community — encouraging unprecedented public-private collaboration among industry, research, academia and government. Dr.
Windham-Bannister is former managing vice president of the
Commercial Strategy Group for Abt Bio-Pharma Solutions Inc.
She was a member of Abt Bio-Pharma Solutions’ corporate
management team, and a founding member of the commercial
division of Abt Associates, the parent company. Dr. Windham-
Bannister has 35 years of consulting experience in life sciences
and has worked with companies that represent all major
industry sectors. She has co-authored two books: Competitive
Strategy for Health Care Organizations and Medicaid and Other
Experiments in State Health Policy. Dr. Windham-Bannister
holds a B.A. from Wellesley College, a doctorate in health policy
and management from the Heller School at Brandeis University,
and was a post-doctoral fellow at Harvard University’s John F.
Kennedy School of Government. She completed her doctoral
work under a fellowship from the Ford Foundation.
Eyal Zimlichman, M.D.
Eyal Zimlichman is an internal medicine physician trained in
Israel, and an expert in medical quality assurance, patient safety
and treatment standards with specific focus on health information technology. A member of the Israel-based Talpiot Medical Leadership Program, a research associate at the Center for
Patient Safety Research and Practice in Brigham and Women’s
Hospital and Harvard Medical School, and a participant in an
executive health management studies at Harvard University.
Prior to moving to Boston, Dr. Zimlichman held a number of
health care management responsibilities, including assistant
to the CEO at Sheba Medical Center, the largest medical center
in Israel, and a number of key positions in the administration
of the IDF Medical Corps. As head of the Quality Management
Section in the Medical Corps he developed and coordinated
the IDF’s medical quality assessment program, and was the
founder and subsequently, the associate editor of the Journal of
Israeli Military Medicine. Dr. Zimlichman is a recipient of the IDF’s
Chief-of-Staff Award of Excellence, 2003.
BALL CONSULTING GROUP
At the Nexus of Life Sciences
and Public Relations
One Gateway Center, Suite 406, Newton, MA 02458
P: 617-243-9950 F: 617-243-9953 www.ballcg.com
18
Speaker Bios
Think Forward
You want to move your research and ideas forward. Our truly versatile, worldwide
team of attorneys is here to remove roadblocks and navigate the obstacles in
your path. As a law firm that has supported the life sciences industry since its
inception, Mintz Levin has helped hundreds of companies raise capital, manage
operations, protect intellectual property, develop products, recruit and retain talent,
resolve disputes, enter into complex partnerships, and go public.
Mintz Levin is an AmLaw 100 firm with eight offices in the U.S. and UK and a liaison
office in Israel, strategically located to meet the evolving needs of our clients
located around the world. We have had an active presence in Israel for almost a
decade, and we nurture a strong commitment to the Israeli marketplace.
For more information, please contact:
Jonathan Kravetz at JLKravetz@mintz.com or Yael Biran at YBiran@mintz.com
Information contained herein may be considered attorney advertising. Prior results do not guarantee a similar outcome. 0680
Boston | London | Los Angeles | New York | Palo Alto | San Diego | Stamford | Washington
www.mintz.com
2010 Life Sciences Summit
19
COMPANY PROFILES
Biokine Therapeutics
Biokine Therapeutics Ltd. is an emerging biotechnology company developing novel
drugs for cancer patients including anti-cancer and stem cells mobilization drugs.
Biokine was established in 2000 by Prof. Amnon Peled from Hadassah University
Hospital in Jerusalem and Dr. Orly Eizenberg. The company is focused on developing new and novel CXCR4 based drugs and has completed Phase I/IIa clinical trials
in 16 multiple myeloma patients.
Leading Product and TechnologyHit platform:
The CXCR4 axis is critically involved in the development and progression of cancer
as well as in regulating stem cell mobilization and the recovery of the bone marrow
following chemotherapy and inflammation.
BKT140, the most advanced molecule of Biokine, is a unique CXCR4 antagonist.
Through extensive pre-clinical research Biokine discovered that BKT140 is an anticancer agent with the capacity to treat lymphoma, leukemia, multiple myeloma and
solid tumors as well as a powerful mobilizer of stem cells and lymphocytes.
www.biokine.com
Yossi Riback
Chief Executive Officer
Rehovot, Israel
email: yossi.riback@biokine.com
Yossi Riback
Yossi Riback is the CEO of BioKine Therapeutics Ltd. He is a professional manager with Financial, Markets and Regulatory expertise with over 30 years of
experience in Israeli and international markets. Yossi holds an LLB degree from
the Hebrew University in Jerusalem. Mr. Rubin has served at the Israel Ministry
of Finance, also as a key trouble shooter during times of severe economic and
financial crisis in Israel (early 1980s). Subsequently he was part of Poalim Capital
Markets and Investments senior management. This was followed by running
Discount Capital Markets and Investments. Both these Institutions are key players in Israeli Investment Banking and Markets. Among others, these activities
included Equity Capital Markets, M&A and Private Equity. The latter included the
initiation and sponsorship of a wide range of funds covering high tech, biotech
and private equity and mezzanine finance.
20
Company Profiles
Dynamix Pharmaceuticals
Dynamix is a venture-backed pharmaceutical company focused on the discovery
and development of novel, targeted, small-molecule drugs for cancer and autoimmune disorders. Dynamix focuses on two drug classes – Cancer Metabolism modulators and Type II Kinase Inhibitors. Both drug classes explore some of the newest
and most promising therapeutic routes to treat urgent, unmet medical needs in
cancer and autoimmune disorders.
Dynamix is building an industry-leading pipeline of small-molecule drugs. Founded
in 2009, Dynamix has already created a strong pipeline of 6-drug programs across
cancer metabolism, cancer and autoimmune disorders, and is currently focusing on
the optimization and preclinical development of these candidates. The company
will start clinical development of its lead program in 2011. Among the programs
under development are:
r 1ZSVWBUF,JOBTF.1,.
BDUJWBUPSTGPSSFOPSNBMJ[JOHDBODFSNFUBCPMJTN
r 1-,JOIJCJUPSTGPSDPMPSFDUBMBOECSFBTUDBODFSGPDVTJOHPOQNVUBUFE
tumors (personalized medicine)
r 4FMFDUJWF5ZQF**4:,JOIJCJUPSTGPSBVUPJNNVOFEJTPSEFSTQBSUOFSFEXJUI
Teva Pharmaceuticals)
r 4FMFDUJWF5ZQF**+",JOIJCJUPSTGPSBVUPJNNVOFEJTPSEFST
www.dynxp.com
This home-grown pipeline was created with the company’s highly efficient discovery platform and innovative proprietary DynamixFit™ technology. This technology
platform addresses the process of ‘dynamic induced fit’, in which the 3D structure
of the target protein changes when it interacts with drug compounds. It is uniquely
suitable for discovering novel selective kinase inhibitors, is able to identify NCEs
even for ‘tough’ targets, significantly shortening drug development times, and lowering R&D costs.
Oren Becker, Ph.D.,
President and Chief Executive Officer
Rehovot, Israel
email: obecker@dynxp.com
Oren Becker, Ph.D.
Dr. Becker has more than 19 years of leadership and management experience
in pharmaceutical drug discovery and development. Since founding Dynamix
Pharmaceuticals in 2009, Dr. Becker serves as its President and CEO. Prior to that
he was co-founder and CSO of Predix Pharmaceuticals Inc., which merged with
Epix Pharmaceuticals Inc. (NASDAQ) for $125 million, and signed $1.5 billion
worth of deals with GSK and Amgen. Dr. Becker is former CSO of Epix Pharmaceuticals, where he led the discovery of five drugs in clinical development. He
is also formerly a professor at Tel-Aviv University and a visiting professor at Harvard University. He holds a Ph.D. from Hebrew University and did post-doctoral
studies at Harvard University.
Company Profiles
21
ElMindA
ElMindA’s mission is to revolutionize the way we treat brain disorders, by opening a new window into the way the brain works. Founded in 2006, ElMindA has
developed the Brain Network Activation (BNA) technology, which for the first time
enables elucidation of the neural activity at high temporal and spatial resolutions,
capturing information on the composition, connectivity, synchronization and operation of brain networks.
functional brain imaging
An astounding 1 in every 3 people suffers from a brain-related illness (Alzheimer,
ADHD, stroke, depression, epilepsy, stroke, etc), causing an enormous economic
and social burden that continues to grow as the population ages. To date, the treatment and management of these disorders have been largely based on subjective
assessment and trial and error. ElMindA’s BNA technology can transform the practice of medicine for the treatment of brain-related disorders, enabling more exact
diagnosis and better treatment selection, assessment and optimization, enhancing
treatment efficacy and patients’ quality of life while reducing costs.
ElMindA’s platform technology is applicable to a wide spectrum of indications
including ADHD, Stroke, Epilepsy, Alzheimer’s Disease, Multiple Sclerosis, Pain and
more. The first 2 applications in the pipeline are: (i) A medical device for treatment
management of ADHD by accurate and objective diagnosis, treatment selection
and optimization; and (ii) A critical tool for pharmaceutical and neuro-stimulation
companies to accelerate and improve treatment development by supporting crucial decisions to increase the success rate of clinical trials (more appropriate dose,
more responsive subjects, higher efficacy).
www.elminda.com
ElMindA enjoys a broad IP base, an experienced management team, and a world
class scientific advisory board. The company has already completed several clinical
studies at leading institutes, and secured a strategic collaboration with Kendle International (NASDAQ: KNDL), a leading, global full-service clinical research organization (CRO). As of March 2010, ElMindA’s first product is commercially available, and
has started generating revenues for the company.
Ronen Gadot
Managing Director
Herzliya, Israel
email: ronen@elminda.com
Ronen Gadot
Before joining ElMindA in 2006 as its first investor and Managing Director,
Ronen Gadot had extensive management and entrepreneurial background
including: CEO of SHL Telemedicine Europe, a leading telemedicine based
disease management operation, and Executive VP of the SHL Group; Founding
team-member of Philips Electronics Corporate Venture Capital arm and Director
of Business Development & Venturing, with numerous investments, commercial
agreements and board memberships in entrepreneurial companies; and operations and marketing management positions at Silicon Valley based Applied
Materials; and an 8 year Air Force career. Mr. Gadot holds a B.Sc. in industrial
engineering and an MBA from INSEAD.
22
Company Profiles
Galmed Medical Research
GalMed Medical Research develops innovative, proprietary drugs for the treatment
of chronic lipid related and liver diseases. The most advanced compound, Aramchol,
is initiating these days a phase-II clinical trial in patients with Fatty Liver (NAFLD and
NASH). The company has successfully completed Phase I studies with oral Aramchol
in 41 human volunteers with excellent safety and pharmacokinetics results. Aramchol is a once daily, orally administrated, new synthetic small molecule that has
already demonstrated efficacy in a variety of experimental models and in human
cells and safety in chronic toxicology studies. Aramchol’s activity was demonstrated
to be due to an inhibition of the liver lipogenic enzyme Stearoyl Coenzyme A
Desaturase (SCD).This inhibition caused decreased fatty acid synthesis on the one
hand with simultaneously increased fatty acid catabolism (beta oxidation) on the
other hand. There are at present no known inhibitors of SCD1 with the established
safety and efficacy profile of Aramchol which has also marked hypocholesterolemic
and modest Anti atherogenic activity.
Non-alcoholic fatty liver disease (NAFLD) is the most frequent chronic liver disease
worldwide. Its prevalence in the general population of the industrialized countries
is >30% and its rising rapidly together with the occurrence of obesity and diabetes.
The prevalence of non alcoholic steatohepatitis (NASH), the progressive form of the
disease, is 4-6% of the general population. Recently fatty liver was shown to carry a
5 fold increased risk of severe CVD complications within 5-6 follow up. At the present time, no treatments are available for NAFLD or NASH.
www.galmedgroup.com
The gastrointestinal (GI) disorders market has been one of the largest and most
profitable therapeutic areas in the world pharmaceutical industry. It is estimated
that an Aramchol-based fatty liver disease drug’s annual sales could amount to
more than $15 billion worldwide.
Itzchak Angel, Ph.D.
Chief Executive Officer
Allen Baharaff
Chief Financial Officer
Tel Aviv, Israel
email: itzchak@galmedgroup.com
Allen Baharaff
Allen Baharaff is a trained solicitor and a member of the Israeli bar since 1993.
He holds a B.Sc. degree in economics from the London School of Economics
and an MA. LLB. degree from Cambridge University. Mr. Baharaff is formerly a
senior consultant at Shaldor Management Consulting Co. He has been acting as
GalMed’s CFO since its incorporation.
Company Profiles
23
ITGI Medical
ITGI Medical is an Israeli bio-medical engineering company specializing in research
and development, design, manufacture and distribution of high quality heterologous tissue covered stents for cardiovascular and neurovascular interventions. ITGI
has proprietary patents, techniques and devices to cover stents with heterologous
tissue. Our proprietary technology and knowledge in working with heterologous
tissue is propelling our growth. We are focusing on current technologies and application that improve the standard of care for patients around the world in the
fields of interventional cardiology and neurology for the application in coronary
and neurological aneurysms, Saphenous Vein Graft occlusion (SVG disease) and
vascular perforations. Studies conducted prove that ITGI’s propriety technology can
address these clinical problems in a safe and effective manner.
Israel Schreiber
Chief Executive Officer
Or Akiva, Israel
email: israels@itgimedical.com
www.itgimedical.com
Israel Schreiber
Israel Schreiber has over 25 years of managerial experience in the biotechmedical industry in Israel and in the U.S. Mr. Schreiber served as the CEO and
president of Itamar Medical Ltd. (symbol ITMR in TASE) for the past 10 years
and as the president of its U.S. subsidiary, Itamar Inc. Mr. Schreiber has led
the company, transitioning it from a small R&D group to a well-recognized
provider of innovative, multi-million, diagnostic systems for rapidly growing and proven clinical applications. Previously to Itamar, Mr. Schreiber held
senior positions with Elscint Ltd., a publicly traded medical imaging company.
Working in Israel and in the U.S., he led a new business concept of an integrated solution for medical imaging equipment and remote data handling and
analysis. Mr. Schreiber holds a B.Sc. degree in mechanical engineering and an
MBA degree, both from the Technion-Israel Institute of Technology, Haifa.
24
Company Profiles
Mazor Robotics
Mazor Surgical Technologies has pioneered the development of miniature semi-robotic bone-mounted positioning systems SmartAssist platform for a wide range of
orthopedic procedures. Mazor is a leading provider of SpineAssist, a highly accurate,
minimally invasive, easy-to-use, miniature surgical assistance system for a wide
range of spine procedures. Established in 2001and sponsored by the TechnionIsrael Institute of Technology, Mazor’s SpineAssist system is in regular use in medical
centers worldwide.
Mazor’s proprietary technology enables a safer environment for patients, surgeons
and OR staff, by utilizing miniature robotic, imaging and implant technologies. Our
products SpineAssist®, C-InSight™ and GO-LIF™ are easy-to-use, cost-effective and
improve surgical outcomes.
Ori Hadomi
Chief Executive Officer
Caesarea, Israel
email: O.Hadomi@mazorst.com
www.mazorst.com
Ori Hadomi
Ori Hadomi is CEO of Mazor Surgical Technologies. A seasoned financial and
business leader, Mr. Hadomi was CFO and VP of Business Development at DenX
(image-guided dental surgery), Founder and CEO of 7D Ltd. (motion tracker for
medical applications), and Chairman of the Izmel Scientific committee (consortium for the image-guided industry).
Company Profiles
25
NasVax
NasVax develops novel and improved vaccines and immunotherapeutic products.
The company has four programs:
1. Anti-CD3 (aCD3) oral immunotherapy employs a monoclonal antibody for
down-regulating pathogenic immune cells in inflammatory and auto-immune diseases. The aCD3 program is in its initial Phase 2a study in subjects
with nonalcoholic steatohepatitis (NASH or fatty liver disease). The company
has an ongoing collaboration with Centocor Ortho for aCD3.
2. VaxiSome® adjuvant / delivery-system is formulated to enhance the immunogenicity of vaccines and immunotherapeutics. VaxiSome-Influenza
vaccine has been evaluated in Phase 1-2a clinical studies. The company has
an ongoing non-exclusive collaboration with Novartis for VaxiSome®.
3. Group-common protein-based pneumococcal vaccine is a potential 3rdgeneration vaccine that has potential advantages over the currently marketed 2nd-generation vaccines. The company has an ongoing collaboration
with GlaxoSmithKline (GSK) for part of the pneumococcal vaccine program,
which is in preclinical studies.
4. Alzheimer’s disease immunotherapeutic based on a novel monoclonal antibody, which is in preclinical studies.
www.nasvax.com
NasVax has collaborations with three of the largest pharma companies. The company seeks to provide its future partners with access to its programs via licensing
and joint development arrangements, and to enable utilization of the VaxiSome
platform for additional indications and applications not being actively explored by
the company, including immunotherapy. NasVax also seeks access to novel vaccine
antigens.
Rom Eliaz
Chief Executive Officer
Ronald Ellis, Ph.D.
Senior Vice President, Research & Development
Ness-Ziona, Israel and San Jose, CA
email: rom@nasvax.com
Ronald Ellis, Ph.D.
Dr. Ellis, Senior VP R&D and Chief Technology Officer for NasVax, Ltd., has 28
years of scientific, managerial and executive R&D experience for biological
products in small, medium and large biotechnology/pharmaceutical companies
in the U.S. and during the last three years in Israel. He has championed or led
R&D efforts on a wide range of viral and bacterial vaccines and biotherapeutics from discovery or in-licensure through development and on to product
licensure and launch for five major products in U.S./EU markets. Dr. Ellis is coauthor of over 100 publications and 35 review articles, editor of eight books on
vaccines, and is founding and incumbent editor-in-chief of Human Vaccines, the
second peer-reviewed indexed vaccine journal launched in 2005.
26
Company Profiles
Navotek Medical
Navotek Medical Ltd, founded in 2005, has developed the proprietary RealTrack™,
intra-body tracking technology, enabling real-time, 3D tracking of tiny radioactive
sources within the human body with sub-millimeter accuracy.
Navotek is currently marketing its first products:
r 3FBM&ZF–USBDLJOHTZTUFN
r 5SBDFSJNQMBOUBCMFñEVDJBMNBSLFST
The system provides real-time localization of tumors before and during external
beam radiation therapy treatments.
The RealEye and Tracer performance was verified in multicenter studies that have
proven its accuracy, objectivity and significant time saving. Moreover, sub-millimeter, real-time target localization has the potential to significantly reduce the treatment course length from 30-40 treatments to 5-10 (hypo-fractionation and SBRT).
Navotek is in the process of developing its next applications, augmented reality
based navigation systems for guided surgery.
Navotek’s team is composed of highly talented individuals that work together as a
closely knit team. Each of the members contributes from his directly relevant experience to the company’s rapid and successful progress.
www.navotek.com
Giora Kornblau
Chief Executive Officer
Yokneam, Israel
email: Giora.k@navotek.com
Giora Kornblau
Prior to founding Navotek, Mr. Kornblau held the position of R&D manager,
responsible of the field of high-end defense industry tracking technologies at
Elbit system. In this job he led the development of electro-magnetic, optical
and inertial tracking systems. Prior to that, he served in the Israel Defense Force
as a fighter pilot. Mr. Kornblau graduated from the IDF “Talpiot” Project, a special
program qualifying research and development officers for the IDF. Mr. Kornblau
is a cum laude graduate in mathematics and physics from Hebrew University,
Jerusalem.
Company Profiles
27
Neuronix
Founded in 2008, Neuronix mission is to provide long-term improvement in the
quality of life for patients with Alzheimer’s disease, an incurable and terminal disease affecting 26 million people worldwide.
The company’s solution, NICE™, is based on a novel, patented technology, using
transcranial magnetic stimulation (TMS) of affected brain regions simultaneously
with cognitive training. The stimulation is believed to induce long-term potentiation (LTP), known to be associated with learning and memory. The result is a measurable cognitive improvement after just a few weeks of treatment.
A clinical study conducted in Israel has shown promising results from both safety
and efficacy perspectives, recording improvement in lost cognitive function of
Alzheimer’s disease at least as good as that of existing drugs. Moreover, this improvement seems to be long-lasting up to a period of over a year. A CE mark for the
treatment is currently pending.
Eyal Baror
Chief Executive Officer
Yoqneam, Israel
email: eyal@neuronixmedical.com
www.neuronixmedical.com
Eyal Baror
Eyal Baror is CEO of Neuronix Ltd. He brings over 10 years of experience in R&D,
including several C-level positions in Medical Devices Companies. A graduate of
the prestigious Talpiot program, he holds a B.Sc. in physics (cum laude) from the
Hebrew University, Israel, and an M.Sc. in physics (summa cum laude) from the
Tel Aviv University, Israel.
28
Company Profiles
NovoCure
NovoCure’s NovoTTF-100A is a non-invasive, portable medical device for the treatment of cancer utilizing low intensity alternating electric fields. Initial indications
for use are primary brain tumors (glioblastoma multiforme) and late stage nonsmall cell lung cancer. NovoCure’s Tumor Treating Fields (TTFields) are a completely novel approach to
fighting cancer targeted at the physical properties of rapidly dividing cells with no
toxicity. Early studies show promising efficacy when compared to standard chemotherapy with the only known side effect to be mild to moderate skin irritation under
the surface electrodes.
William Doyle
Chairman
Asaf Danziger
Chief Executive Officer
Haifa, Israel
email: asaf@novo-cure.com
www.novocuretrial.com
William Doyle
Bill Doyle is chairman of NovoCure Ltd. and managing director of WFD Ventures
LLC, a New York-based venture capital firm he co-founded in 2002. Previously,
Mr. Doyle was a member of Johnson & Johnson’s Medical Devices and Diagnostics Group operating committee and vice president, licensing and acquisitions.
At J&J, he was also chairman of the Medical Devices Research and Development
Council, worldwide president of Biosense-Webster and a member of the board
of directors of Cordis and Johnson & Johnson Development Corporation, J&J’s
venture capital subsidiary. Mr. Doyle holds a B.S. in materials science and engineering from MIT and an MBA from Harvard Business School.
Company Profiles
29
Protalix Biotherapeutics
Protalix Biotherapeutics is focused on the development and commercialization of
recombinant therapeutic proteins based on their proprietary ProCellExTM protein
expression system.
Using our ProCellEx platform, Protalix is developing a pipeline of proprietary recombinant therapeutic proteins that target large, established pharmaceutical markets
and that rely upon known biological mechanisms of action. The initial commercial
focus has been on complex therapeutic proteins, including proteins for the treatment of genetic disorders, such as Gaucher disease and Fabry disease. Protalix believes the ProCellEx protein expression system will enable us to develop proprietary
recombinant proteins that are therapeutically equivalent or superior to existing
recombinant proteins currently marketed for the same indications.
Protalix currently has agreements with Pfizer, Teva Pharmaceuticals, Weismann
Institute of Science and others.
David Aviezer, Ph.D.
President and Chief Executive Officer
Sandra Lauterbach
Vice President, Sales and Commercial Operation
Carmiel, Israel
email: david@protalix.com
www.protalix.com
Sandra Lauterbach
Sandra Lauterbach brings over 20 years of expertise in U.S. and global marketing, commercial strategy and product development for pharmaceutical and
biotechnology companies. Prior to joining the company, she served as vice
president of marketing, endocrinology at EMD Serono and senior director,
global marketing for Fabrazyme at Genzyme Corporation. Her background also
includes several years with in the auto-immune therapeutic arena at Vertex
Pharmaceuticals Inc. and Amgen. She began her career at Merck Human Health
as a hospital sales professional. Her experience and track record with prelaunch and launch activities are extensive, especially within the biologic space.
Ms. Lauterbach received her B.S. in molecular biology from the University of
Wisconsin and her MBA from the University of South Florida.
30
Company Profiles
Proteologics
Proteologics is a biopharmaceutical company exploiting the ubiquitin system for
the discovery and development of novel therapeutics. Drs. Avram Hershko and
Aaron Ciechanover, — 2004 Nobel Prize in chemistry laureates for the discovery of
the ubiquitin system — lead our distinguished scientific advisory board. Proteologics’ world-class knowledge, supported by a unique target and drug discovery
platform, is being used to unveil the role of ubiquitin in pathologies with the goal
of developing ubiquitin system targeted drugs for many types of cancer, metabolic
disease, viral infections and CNS related disorders.
Proteologics identifies correlations between ubiquitin pathway components and
pathological conditions. Once specific E3 targets are being selected and validated,
we proceed to establishing proprietary technologies for the accelerated hit-to-lead
drug discovery process. Proteologics’ recognized competencies are built through a
number of internal programs and partnerships, including strategic R&D collaborations with Glaxo Smith Kline (GSK) and Teva Pharmaceutical Industries Ltd.
Avishai Levy
Chief Executive Officer
Daniel Taglicht, Ph.D.
Director of R&D
Rehovot, Israel
email: avishai@proteologics.com
www.proteologics.com
Daniel Taglicht, Ph.D.
Daniel Taglicht is director of R&D for Proteologics Ltd., which he joined in 2001
as head of molecular biology. He started his professional carrer as an R&D scientist at Sigma-Aldrich (Jerusalem). Dr. Taglicht earned his B.Sc. in biology with
honors (1985), M.Sc. in microbiology with honors (1987) and Ph.D. in microbiology (1991) from the Hebrew University of Jerusalem. He was a postdoctoral
fellow in the laboratory of Dr. Susan Michaelis at the Johns Hopkins School of
Medicine.
Company Profiles
31
Regentis Biomaterials
Regentis Biomaterials is a tissue repair company that is developing and commercializing innovative biodegradable hydrogels for the local repair of damaged cartilage
and bone. Our platform technology is a family of hydrogels called Gelrin™. These
gels can be injected or applied to a specific local site and offer beneficial properties
for the local repair of damaged tissue such as cartilage and bone.
The Gelrin™ technology offers off-the-shelf products that are designed to be suitable for both open surgery and minimally invasive procedures. An ideal solution
for physicians and their patients, the products are easy to implant and have been
shown to stimulate the regeneration of healthy cartilage and bone tissue. Regentis’
first orthopedic product is GelrinC, a biodegradable hydrogel for articular cartilage
regeneration. Additional pipeline products include GelrinB — a biodegradable
hydrogel for bone regeneration; and GelrinA — a void-filling matrix for aesthetic
indications.
Extensive preclinical studies have demonstrated both the safety and efficacy of Gelrin™ and initial human clinical trials in Europe in preparation for CE mark approval
have started. Human trials under an IDE are expected to begin in early 2011.
Alastair Clemow, Ph.D.
President & Chief Executive Officer
Or-Akiva, Israel
email: aclemow@regentis.co.il
www.regentis.co.il
Alastair Clemow, Ph.D. Alastair Clemow brings 30 years of orthopaedic management experience to
Regentis. He was previously CEO and founder of multiple orthopaedic companies including Nexgen Spine, Gelifex (sold to Synthes) and MIST (sold to Mako
Surgical:NASDAQ). Prior to this, Dr. Clemow spent 19 years with Johnson &
Johnson where he held a number of executive positions including vice president of business development at both Johnson & Johnson Professional and
Ethicon EndoSurgery. Dr. Clemow has sat, or currently sits, on the board of
numerous companies including Encore Surgical (sold to Blackstone Capital),
Medgenics, BioMedical Enterprises and Kinetic Muscles. Dr. Clemow holds a
B.Sc. and Ph.D. from the University of Surrey (UK) and an MBA from Columbia
University and is a fellow of AIMBE and a past-president of the Society for Biomaterials.
32
Company Profiles
TransPharma Medical
TransPharma Medical™ is a specialty pharmaceutical company focused on the
development and commercialization of biopharmaceutical products utilizing our
proprietary zactive transdermal drug delivery technology. TransPharma’s ViaDerm
delivery system is a low-cost home use system especially designed for self, safe and
simple application by the patient. It is suitable for transdermal delivery of a wide
range of molecules including biologics.
We are currently pursuing three transdermal drug-product development programs.
Our lead product is the ViaDerm-hPTH(1-34), for the treatment of osteoporosis, in
collaborative development with Eli Lilly. The product is currently in Phase IIB. Our
Phase IIA human clinical trials, in which ViaDerm-hPTH (1-34) was administered
repeatedly to 104 osteoporosis patients for 96 successive days, has met its primary
and secondary endpoints for efficacy and safety. Two other, high-potential peptide
based products are currently in Phase I. One of these products is the ViaDerm-GLP-1
agonist for the treatment of type 2 diabetes, currently in Phase IB. TransPharma
has identified significant advantages that its ViaDerm-GLP-1 agonist product in
development may offer over the current injectable marketed products. Already, our
Phase IA study results demonstrated a clearly preferable sustained drug PK profile.
The sustained drug profile may allow for once a day painless transdermal administration with lessened side effects associated with the current injected peak drug
blood profile. TransPharma has established an infrastructure for product development including
pilot manufacturing lines.
www.transpharma-medical.com
Daphna Heffetz, Ph.D.
Chief Executive Officer
Lod, Israel
email: Daphnah@transpharma.co.il
Daphna Heffetz, Ph.D.
Dr. Heffetz is founder, CEO and board director of TransPharma Medical, where
she has raised $34 million from leading a venture capital firm. The company’s
lead product, ViaDerm-hPTH(1-34), was out-licensed to Eli Lilly. TransPharma
was granted an upfront payment of $35 million and may also receive development and sales milestones, as well as royalties on future sales. Prior to joining
TransPharma, Dr. Heffetz served as CEO and director of Savyon Diagnostics
from 1998 to 2000 and was responsible for substantial increases in the overall
profitability of the company. From 1994-1998, Dr. Heffetz served as operations
manager and R&D project leader at Savyon. Dr. Heffetz received her Ph.D. in
biochemistry from the Weizmann Institute of Science in 1991, followed by a
postdoctoral fellowship in molecular biology. She has published numerous
articles in leading scientific journals, and has been the recipient of a number of
academic awards and prizes.
Company Profiles
33
About the New England-Israel Business Council
The New England-Israel Business Council (NEIBC) is a non-profit, non-governmental,
membership-supported organization that connects companies and investors in New
England to Israel. One of the fastest growing economies among developed nations in the
world, Israel, like the U.S., is one the major centers for innovation and entrepreneurship in
technology and life sciences.
With a similar industrial focus and an entrepreneurial culture, New England and Israel
share a natural economic affinity. Academic initiatives, as well as state and federal policy
initiatives, reinforce and nurture scientific and business collaboration between the two
regions.
The NEIBC supports this collaboration. Our goals are to:
Foster cooperation, investment opportunities and business relationships between
Israeli and New England companies
Support business, academic and government organizations in New England and
Israel wishing to develop mutual relationships
Assist Israeli companies seeking to establish a U.S. presence
Please contact NEIBC to learn more corporate sponsorship and membership.
info@neibc.org
Tel: (617) 610-0077
120 Wells Avenue, Newton, MA 02459
New England-Israel Business Council
2010 Life Sciences Summit
34
NEIBC
NEIBC Past Events and Programs
2010
Homeland Security Event featuring a delegation of 12
Israeli homeland security companies with keynote speaker Mary
Elizabeth Heffernan, Massachusetts secretary of public safety and
security
The Resilience of Israel’s Economy private breakfast with Dr.
Yuval Steinitz, Israeli minister of finance.
Brain Research in Israel Today: Reality and Vision.
2009
Cleantech Israel featuring Craig “Hezi” Kugler, former director
general of Israel’s Ministry of Infrastructure.
The CEO’s Dilemma – How to Drive Efficient Innovation in the
Organization presentation by Joe Barkai, practice director Product
Lifecycle Strategies, IDC Manufacturing Insights.
2009 New England – Israel Life Sciences Summit featuring 13
Israeli life sciences companies presented to and met with potential
strategic partners and investors. Presentation by Israel Makov,
former CEO of Teva Pharmaceuticals and chairman of Given Imaging
and Netafim.
Global Financial Markets and Investing in Israeli Assets.
Investment Opportunities in Israeli Mobile and Communication
Startups.
Israel Makov, Chariman, Given Imaging
Keynote speaker
2009 Life Sciences Summit
2008
Bio-Pharma in Israel and Collaborative Opportunities Between
New England & Israel – The Genzyme Model featuring Zeev Zelig,
VP and GM of ITG region Genzyme, and Oved Amitai, GM Gaucer
Disease, Genzyme.
Israel Cleantech Investors’ Conference hosting a delegation of 15
companies and local investors with keynote speakers Deval Patrick,
governor of Massachusetts, and Booky Oren, CEO of Miya Arison
Group and chairman of Watec.
Leadership the Hard Way featuring Dov Frohman, founder and
former general manager of Intel, Israel.
Innovation in Israel at 60 featuring David Anthony, Israel Venture
Capital Research Center.
Water: “More Precious than Oil – Challenges, Management and
Investment Opportunities” featuring Simon Tal, former water
commissioner of Israel and founder of Tal Content and a panel of
leading industry experts.
The Strong Israeli Economy featuring Dr. Yaakov Fisher’s analysis of
trends in the fast growing Israeli economy.
Security Technologies of the Future featuring Kevin M. Burke,
Massachusetts secretary of public safety and a panel of security
experts.
Kickoff event at the John F. Kennedy Presidential Library addressing
the dynamic U.S.-Israel mergers & acquisitions scene featuring
Michael Ruettgers, retired chairman and CEO of EMC.
Massachusetts Gov. Deval Patrick
2008 Israeli Cleantech Investor’s Conference
NEIBC
35
NEIBC Executive Board and Advisors
Executive Board
President
Yuval Malinsky
CEO
Vigorous Mind
Adi Golani
Director of Economic Affairs
Consulate General of Israel to
New England
Avi Nevel
President
Nevel International
NEIBC Rhode Island Representative
Secretary
Gil Breiman
Partner
Burns & Levinson
Nancy Katz
Director, Israel Advocacy
Combined Jewish Philanthropies
Don Perrin
Principal
Cambridge Business Advisors
NEIBC Chair, Special Projects
Treasurer
Bruce Levine
Partner
Levine, Katz, Nannis + Solomon
David Barone
Principal
Boston MedTech Advisors
NEIBC Life Sciences Committee Chair
David Crosby
Counsel
Nixon Peabody
NEIBC Cleantech Committee Chair
Minde Kornfeld
Independent Business Counsel
NEIBC Membership Committee Chair
Udi Mokady
CEO
CyberArk
NEIBC Information Technology and
Communications Committee Chair
Mel Prenovitz
CEO
EndoSphere Surgical
NEIBC Marketing Committee Chair
Perry Newman
President
Atlantica Group
NEIBC Maine Representative
Directors
Shy Baranov
Partner
ZAG/SW LLP
Robert Gottlieb
Principal
RMG Associates
Yael Biran
Managing Director
Mintz Levin Israel Business
Tamar Guy
Executive Director
America-Israel Chamber of Commerce
Albert Sherman
Vice Chancellor
University of Massachusetts Medical
School (retired)
Robin Blatt
Principal
Applied Biogenuity
Yigal Koltin
Independent Biopharmaceutical
Consultant
Jeff Stonberg
Principal
Stonberg Holdings Corp.
Gary Engelson
Partner
Lowrie, Lando & Anastasi
Jerry Schaufeld
Professor of Management
Worcester Polytechnic Institute
Gill Fishman
Owner
Gill Fishman Design Associates
Ilan Segev
Vice President, Private Banking
Credit Suisse
Advisory Board
Yair Shiran
Economic Minister to North America
Government of Israel
36
NEIBC
Jack M. Wilson
President
University of Massachusetts System
Edward Shapiro
Edward A. Shapiro, P.C.
2010 Life Sciences Summit Committee Members
Oved Amitay
Vice President and General Manager,
Gaucher Disease Portfolio
Genzyme Corporation
Shy Baranov
Partner
ZAG/SW LLP
David Barone
Principal
Boston MedTech Advisors
NEIBC Life Sciences Committee Chair
Martin Becker
Biotechnology Consultant
Yael Biran
Managing Director
Mintz Levin Israel Business
Robin Blatt
Principal
Applied Biogenuity
Kathryn Bloom
Biogen Idec (retired)
Gil Breiman
Partner
Burns & Levinson
Howard Brick
COO
MedPanels
Ari Buchler
Senior Vice President and General
Counsel
Phase Forward
Michael Chorev
Associate Professor of Medicine
Harvard Medical School
Dalia Cohen
Chief Scientific Officer
Asterand
Raphael Nir
President
SBH Sciences
Joyce College
Business Development
Automated Medical Instruments
Michal Preminger
Executive Director
Office of Technology Development
Harvard University Medical School
David Dyekman
Member
Greenberg Traurig
Neal Farber
CEO
NeuroHealing
Elkan Gamzu
enERGetic
Biopharmaceutical Consultancy
Robert Gottlieb
CEO
RMG Associates
Henry Kay
Partner
Medica Venture Partners
Yigal Koltin
Biopharmaceutical Consultant
Jon Kravetz
Member
Mintz Levin
Yuval Malinsky
CEO
Vigorous Mind
President NEIBC
Gil Ben Menachem
Director Business Development
Teva Pharmaceuticals
Melvin Prenovitz
CEO
EndoSphere Surgical, Inc.
Yair Schindel
Vice President Marketing, Clinical and
Business Development
Omniguide
Chen Schor
Vice President, Business Development
Global Branded Products
Teva Pharmaceuticals
Martin Sklar
President and CEO
Automated Medical Instruments
Tal Wenderow
Executive Vice President Marketing &
Business Development
Corindus
Sara Dolinsky
NEIBC 2010 Summit Coordinator
Ben Shamir
Business Development and Fundraising
Consultant
NEIBC
37
Partners
American Technion Society (ATS)
The American Technion Society provides critical support to the Technion-Israel
Institute of Technology, ranked among the world’s leading science and technology
universities.
Beacon Alliance
Beacon Alliance facilitates collaborative exchange and research among its industrial,
clinical and academic partners. Our commitment is to foster an environment that
optimizes the development and delivery to commercially viable innovations in
biomedical science and engineering for healthcare applications.
Boston Biomedical Research Institute
Boston Biomedical Research Institute is an independent not for profit institution
dedicated to basic biomedical research to promote the understanding, treatment and
prevention of specific human diseases, and to the training of research scientists.
Jewish Community Relations Council (JCRC)
The Jewish Community Relations Council promotes a society that reflects the best
of American and Jewish values—in Greater Boston, Israel and around the world—by
convening and mobilizing the Jewish community.
Massachusetts Biotechnology Council (MassBIO)
The Massachusetts Biotechnology Council, an association of more than 600
biotechnology companies, universities, academic institutions and others dedicated
to advancing cutting edge research, is the leading advocate for the Bay State’s world
premier life science cluster.
Massachusetts Life Sciences Center (MLSC)
The Massachusetts Life Sciences Center has a mission is to create jobs in the life
sciences and support vital scientific research that will improve the human condition.
This work includes making financial investments in public and private institutions that
are advancing life sciences research, development and commercialization as well as
building ties between sectors of the Massachusetts life sciences community.
Massachusetts Medical Device Industry Council (MassMEDIC)
Massachusetts Medical Device Industry Council seeks to create a positive environment
and united voice for the Massachusetts Medical Device Industry, and to implement
collaborative initiatives which make Massachusetts the medical device research,
development and manufacturing capital of the world.
Massachusetts Technology Transfer Center
The Massachusetts Technology Transfer Center has a government mandate to help any
inventor in any non-profit research institution to commercialize his or her technology.
We help entrepreneurs to start companies and researchers to market their patents
through a broad array of high quality programs and resources.
Medical Development Group (MDG)
Medical Development Group serves the New England region and is a community
of individuals professionally committed to the Medical Device and other Medical
Technology Industry segments united by the belief that innovation and advances in
technology lead to substantial improvements in health care.
38
2010 Life Sciences Summit
NEIBC
Kurzweil
Medical Learning
Harvard GIS Dept
Brand. New !
Whether you need to name one, launch one, brand one or revitalize one,
we approach your company Branding as a member of your team - with creativity and intensity.
From Logo to Website to Marketing Communications, our approach to
your integrated Branding Program will be a team-focused, client-focused effort with successful results that create a unique message for your unique organization.
Gill Fishman Associates
WINNER OF MORE THAN 400 AWARDS FOR BRANDING AND IMAGE CAMPAIGNS
Corporate Design + Branding Cambridge 02139 GillFishmanDesign.com 617. 492.5666
2010 Life Sciences Summit
39
MOITI
Massachusetts Office of International Trade & Investment
Israel Is Proud To Support And Develop
The Technologies For A Better Tomorrow
Overview
The Massachusetts Office of International Trade & Investment (MOITI)
is the international arm of the Commonwealth of Massachusetts.
Foreign Direct Investment
For companies seeking to establish a presence in Massachusetts, MOITI
offers a focused one-stop approach where specialists are enlisted from
state, municipal, and nonprofit organizations to address the foreign
investor’s specific needs and guide them through the process.
Protocol
MOITI is directly responsible for the negotiation and administration of
international agreements on behalf of the Commonwealth of
Massachusetts and also maintains active relationships with over 50
Consular offices operating in Massachusetts.
Export Promotion
For Massachusetts companies looking to make connections abroad,
MOITI hosts Massachusetts Pavilions at large international trade shows
throughout the world. MOITI’s offices in China, Germany, Mexico, and
Brazil also work closely with the Massachusetts Export Center to
promote exports to help firms boost their sales abroad.
MOITI is your one stop shop for international investment.
The Consulate General of Israel to New England:
A Proud Partner In New England –
Israel Business Council 2010 Life Sciences Summit
http:// boston.mfa.gov.il/
+1.617.830.5400
www.mass.gov/moiti
75% of Americans Have a Sleep Disorder
Symptom a Few Nights Per Week or More
You may have a sleep disorder if you experience one or more of
the following symptoms:
• Snoring or waking up gasping for breath
• Not feeling rested or refreshed after sleep
• Tossing and turning during sleep
• Twitching or restless legs at night
• Trouble falling or staying asleep
• Unusual behaviors during sleep
FABER DAEUFER
40
ROSENBERG
2010 Life Sciences Summit
950 Winter Street
Suite 4500
Waltham, MA 02451
www.fdrpc.com
If you suspect you have a sleep disorder, call
Sleep HealthCenters at 877-SLEEP-HC (877-753-3742)
and start getting a good night’s sleep.
Visit Any One of Our Convenient Locations:
Bedford l Beverly l Boston l Brighton l Brookline l Framingham l Jamaica Plain
Marlborough l Medford l Milton l North Dartmouth l Stoughton l Weymouth
Worcester l Cumberland, RI
COMBINED JEWISH PHILANTHROPIES
celebrates the
New England Israel Business Council
for their accomplishments that deepen
the Massachusetts–Israel relationship.
MAY YOU GO FROM
STRENGTH TO STRENGTH
Combined Jewish Philanthropies | 126 High Street| Boston, MA 02110-2700 | www.cjp.org
neibc.org